<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34880312</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Evaluation of a 5-HT<sub>2B</sub> receptor agonist in a murine model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>23582</StartPage><MedlinePgn>23582</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23582</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-02900-0</ELocationID><Abstract><AbstractText>Degeneration of brainstem serotonin neurons has been demonstrated in ALS patients and mouse models and was found responsible for the development of spasticity. Consistent with involvement of central serotonin pathways, 5-HT<sub>2B</sub> receptor (5-HT<sub>2B</sub>R) was upregulated in microglia of ALS mice. Its deletion worsened disease outcome in the Sod1<sup>G86R</sup> mouse model and led to microglial degeneration. In ALS patients, a polymorphism in HTR2B gene leading to higher receptor expression in CNS, was associated with increased survival in patients as well as prevention of microglial degeneration. Thus, the aim of our study was to determine the effect of a 5-HT<sub>2B</sub>R agonist : BW723C86 (BW), in the Sod1<sup>G86R</sup> mouse model. Despite good pharmacokinetic and pharmacological profiles, BW did not ameliorate disease outcome or motor neuron degeneration in a fast progressing mouse model of ALS despite evidence of modulation of microglial gene expression.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnoux</LastName><ForeName>Aliz&#xe9;e</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, Inserm, UMR-S1118, CRBS, Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67000, Strasbourg Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, UR7296, Universit&#xe9; de Strasbourg, 67000, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Domain Therapeutics, 67400, Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayme-Dietrich</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, UR7296, Universit&#xe9; de Strasbourg, 67000, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieterle</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, Inserm, UMR-S1118, CRBS, Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67000, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goy</LastName><ForeName>Marc-Antoine</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, Inserm, UMR-S1118, CRBS, Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67000, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schann</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Domain Therapeutics, 67400, Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frauli</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Domain Therapeutics, 67400, Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Monassier</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, UR7296, Universit&#xe9; de Strasbourg, 67000, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, Inserm, UMR-S1118, CRBS, Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67000, Strasbourg Cedex, France. ldupuis@unistra.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092430">1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044403">Receptor, Serotonin, 5-HT2B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058826">Serotonin 5-HT2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044403" MajorTopicYN="N">Receptor, Serotonin, 5-HT2B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058826" MajorTopicYN="N">Serotonin 5-HT2 Receptor Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>A.A., M.F. and S.S. are employed by Domain Therapeutics. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34880312</ArticleId><ArticleId IdType="pmc">PMC8654833</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-02900-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-02900-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Genetic counselling in ALS: Facts, uncertainties and clinical suggestions. J. Neurol. Neurosurg. Psychiatry. 2014;85:478&#x2013;485. doi: 10.1136/jnnp-2013-305546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305546</ArticleId><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526&#x2013;3539. doi: 10.1093/brain/awaa309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Dentel C, et al. Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: A link to spasticity. Brain. 2013;136:483&#x2013;493. doi: 10.1093/brain/aws274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws274</ArticleId><ArticleId IdType="pubmed">23114367</ArticleId></ArticleIdList></Reference><Reference><Citation>El Oussini H, et al. Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:444&#x2013;456. doi: 10.1002/ana.25030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25030</ArticleId><ArticleId IdType="pubmed">28856708</ArticleId></ArticleIdList></Reference><Reference><Citation>El Oussini H, et al. Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathol. 2016;131:465&#x2013;480. doi: 10.1007/s00401-016-1534-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1534-4</ArticleId><ArticleId IdType="pubmed">26744351</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight AR, et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2004;370:114&#x2013;123. doi: 10.1007/s00210-004-0951-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-004-0951-4</ArticleId><ArticleId IdType="pubmed">15322733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: A family re-united? Trends Pharmacol. Sci. 1995;16:105&#x2013;110. doi: 10.1016/S0165-6147(00)88991-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(00)88991-9</ArticleId><ArticleId IdType="pubmed">7792930</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter GS. Novel discriminatory ligands for 5-HT2B receptors. Behav. Brain Res. 1996;73:149&#x2013;152. doi: 10.1016/0166-4328(96)00087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-4328(96)00087-3</ArticleId><ArticleId IdType="pubmed">8788493</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter RH, et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol. 1999;128:13&#x2013;20. doi: 10.1038/sj.bjp.0702751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0702751</ArticleId><ArticleId IdType="pmc">PMC1571597</ArticleId><ArticleId IdType="pubmed">10498829</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbanti P, Aurilia C, Egeo G, Fofi L, Palmirotta R. Serotonin receptor targeted therapy for migraine treatment: An overview of drugs in phase I and II clinical development. Expert Opin. Investig. Drugs. 2017;26:269&#x2013;277. doi: 10.1080/13543784.2017.1283404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1283404</ArticleId><ArticleId IdType="pubmed">28103158</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. Platelet serotonin level predicts survival in amyotrophic lateral sclerosis. PLoS ONE. 2010;5:e13346. doi: 10.1371/journal.pone.0013346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013346</ArticleId><ArticleId IdType="pmc">PMC2954194</ArticleId><ArticleId IdType="pubmed">20967129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayme-Dietrich E, et al. The role of 5-HT2B receptors in mitral valvulopathy: Bone marrow mobilization of endothelial progenitors. Br. J. Pharmacol. 2017;174:4123&#x2013;4139. doi: 10.1111/bph.13981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13981</ArticleId><ArticleId IdType="pmc">PMC5680644</ArticleId><ArticleId IdType="pubmed">28806488</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, et al. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 2018;173:1073&#x2013;1081. doi: 10.1016/j.cell.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276.e17&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, et al. Natural genetic variation determines microglia heterogeneity in wild-derived mouse models of Alzheimer&#x2019;s disease. Cell Rep. 2021;34:108739. doi: 10.1016/j.celrep.2021.108739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108739</ArticleId><ArticleId IdType="pmc">PMC7937391</ArticleId><ArticleId IdType="pubmed">33567283</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonogaki K, et al. Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. Int. J. Neuropsychopharmacol. 2007;10:675&#x2013;681. doi: 10.1017/S1461145706007206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145706007206</ArticleId><ArticleId IdType="pubmed">16959056</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercruysse P, et al. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain. 2016;139:1106&#x2013;1122. doi: 10.1093/brain/aww004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww004</ArticleId><ArticleId IdType="pubmed">26984187</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671&#x2013;675. doi: 10.1038/nmeth.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesompele J, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:1&#x2013;12. doi: 10.1186/gb-2002-3-7-research0034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2002-3-7-research0034</ArticleId><ArticleId IdType="pmc">PMC126239</ArticleId><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>